US 12,329,808 B2
Compositions and methods for generating an immune response to treat or prevent malaria
Farshad Guirakhoo, Atlanta, GA (US); Arban Domi, Atlanta, GA (US); and Nathanael Paul McCurley, Decatur, GA (US)
Assigned to GeoVax, Inc., Smyrna, GA (US)
Filed by GeoVax, Inc., Smyrna, GA (US)
Filed on Dec. 22, 2023, as Appl. No. 18/394,580.
Application 18/394,580 is a continuation of application No. 17/726,254, filed on Apr. 21, 2022, granted, now 11,857,611.
Application 17/726,254 is a continuation of application No. 16/648,693, granted, now 11,311,612, issued on Apr. 26, 2022, previously published as PCT/US2018/051652, filed on Sep. 19, 2018.
Claims priority of provisional application 62/560,405, filed on Sep. 19, 2017.
Prior Publication US 2024/0398922 A1, Dec. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/015 (2006.01); A61K 9/00 (2006.01); A61K 47/69 (2017.01); A61P 33/06 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/015 (2013.01) [A61K 9/0019 (2013.01); A61K 47/6901 (2017.08); A61P 33/06 (2018.01); A61K 2039/5256 (2013.01); A61K 2039/54 (2013.01)] 17 Claims
 
1. A pharmaceutical composition comprising at least one recombinant modified vaccinia Ankara (MVA) viral vector and a pharmaceutically acceptable adjuvant, wherein the recombinant MVA viral vector comprises:
i) a first nucleic acid sequence encoding a Plasmodium falciparum immunogenic polypeptide selected from the group consisting of circumsporozoite protein (CSP) and gametocyte surface protein P230 (Pfs230), the Plasmodium falciparum immunogenic polypeptide further comprising a transmembrane domain of a glycoprotein (GP) of Marburg virus; and
ii) a second nucleic acid sequence encoding a Marburg virus VP40 matrix protein;
wherein the CSP immunogenic polypeptide comprises the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence at least 98% identical thereto;
wherein the Pfs230 immunogenic polypeptide comprises the amino acid sequence of SEQ ID NO: 6, or an amino acid sequence at least 98% identical thereto;
wherein the Marburg virus VP40 matrix protein comprises the amino acid sequence of SEQ ID NO: 8, or an amino acid sequence at least 98% identical thereto;
wherein both the first nucleic acid and the second nucleic acid sequence are under the control of promoters compatible with poxvirus expression systems; and,
wherein upon expression, the Plasmodium falciparum immunogenic polypeptide and Marburg virus VP40 matrix protein are capable of assembling together to form virus like particles (VLPs).